Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Javier Muñoz | Researchclopedia

Back to researchers

Javier Muñoz

Roche (Switzerland)ORCID

283

Works

19,601

Citations

44

h-index

104

i10-index

Research Topics

CAR-T cell therapy research Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research

Affiliations

Creighton University2024–2024

Roche (Switzerland)2025–2025

University of Maryland, Baltimore2021–2021

Memorial Sloan Kettering Cancer Center2021–2021

The University of Texas MD Anderson Cancer Center2011–2025

Top Works

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu,Frederick L. Locke,et al.

20175,749 citations

Biosimilars and Bioanalytical Methods

Integrated Circuits and Semiconductor Failure Analysis

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke,Armin Ghobadi,et al.

20182,189 citations

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang,Javier Muñoz,et al.

20201,763 citations

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke,David B. Miklos,et al.

20211,435 citations

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil,Michael D. Jain,et al.

2020763 citations

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim,M. Bagot,et al.

2018631 citations

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson,Julio C. Chávez,et al.

2021591 citations

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Constantine S. Tam,Judith Trotman,et al.

2019361 citations

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

Michael Wang,Javier Muñoz,et al.

2022297 citations